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SUMMARY
Objective: To identify the prevalence of clinically significant prescription errors in a Bra-
zilian university hospital compared with their occurrence in 2003 and 2007. Methods: 
Variables and group of variables, such as readability, compliance with legal and institu-
tional procedures of prescription, and prescription errors analysis were analyzed. Re-
sults: When the prevalence rates of clinically significant prescription errors were calcu-
lated, a statistically significant decrease was shown [year of 2003 (29.25%), year of 2007 
(24.20%); (z = 2.99; p = 0.03)], reflecting on the safety rate [year of 2003 (70.75%), year 
of 2007 (75.80%); (z = 3.30; p = 0.0001)]. Conclusion: Despite significant, the increased 
safety rate reflected the quantitative reduction of errors, with no observed  difference in 
severity between the studied periods. Our results suggest the institutional steps taken 
could reduce the number of errors, but they were ineffective in reducing the severity of 
the errors.
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INTRODUCTION
 e use of new technologies in health care has promoted 
improvement in quality and increased life expectancy all 
over the world. However, these breakthroughs have made 
health care increasingly expensive, complex and perme-
ated by risks1-3.
 e negative results in patient care have received sev-
eral names, such as medical errors, adverse events related 
to hospitalization, medicinal iatrogenics, and others. Gen-
erally, the term adverse event is used to designate unin-
tentional damage resulting from medical treatment not 
related to the disease condition. Finally, the study of these 
events has been considered important for the quality of 
patient care and assurance of treatment benefit, a stimu-
lus to the culture of health system safety and e ciency 
(structure, process and result)4. In hospital care, the most 
prevalent adverse events result from inappropriate use of 
drugs (preventable causes) or they are related to patient 
specificities (non-preventable causes), being divided into 
medication errors and adverse reactions to drugs1,2.
Injuries resulting from errors in health services are 
considered the eighth leading cause of death in the United 
States of America2. Forty-four thousand to 98,000 people 
are estimated to die yearly from damage resulting from er-
rors and among these, about 7,000 deaths can be attributed 
to medication errors2. In Brazil, investigations of adverse 
events and medication errors are incipient.
Drugs are essential components in health care and are 
considered the cornerstone in palliative, symptomatic and 
curative treatment in many diseases. However, they are 
also the most common cause of significant adverse reac-
tions, errors and sentinel events5. Errors involving drugs 
occur frequently in hospitals2,6, are multidisciplinary in na-
ture2 and may occur in one or more steps in the therapeu-
tic chain (prescription, dispensation, and administration), 
with a higher frequency upon prescribing7,8. Errors have 
varying rates among institutions6,9,10 and show potential to 
cause adverse outcomes to the patient3, being classified as 
preventable adverse events2. Considering all kinds of er-
rors, each hospitalized patient is estimated to experience 
an average of more than one medication error per day9.
 e prescription is essentially a communication tool 
among the physician, the pharmacist, the nurse, the care-
giver and the patient. In order to be considered appropri-
ate, in addition to being clear, the prescription must follow 
the World Health Organization (WHO) criteria for a ra-
tional prescription which is appropriate, safe, effective and 
economic11.  ese characteristics contribute to better suc-
cess odds for the therapy applied and the patient’s safety3,12.
Adopting tools for a continuous improvement of the 
care process focused on patient safety requires address-
ing the theme “error”, which, in health care, is still under a 
heavy stigma. It is oen associated with low competence, 
shame and punishment, making it di cult to discuss 
study conduction, error reporting and underlying cause3. 
 e current study was conducted in an error systemic view 
focused on processes rather than people and had the pur-
pose of identifying the prevalence of clinically significant 
prescription errors compared with their occurrence in the 
years of 2003 and 2007 in a Brazilian university hospital 
as a way of evaluating the impact of the actions taken to 
improve safety of the prescription process.
METHODS
á is was a descriptive, cross-sectional, comparative study 
with data collection from duplicates of prescriptions con-
taining one or more drugs. Data collection was held in two 
periods: June 1 to 30, 2003 (first sampling) and May 7 to 
13, 2007 (second sampling) in a federal university tertiary 
care public hospital with 243 beds designed to the Unified 
National Health System (SUS) in Fortaleza, Ceará, Brazil.
Within the first sampling period, 9,482 prescriptions 
were dispensed by the Pharmacy, with 474 being collect-
ed (3,460 drugs prescribed). Within the second sampling 
period, 10,500 prescriptions were dispensed, with 140 be-
ing collected (1,030 drugs prescribed). In both samplings, 
10% of dispensed prescriptions each day were selected, 
randomized by conglomerate (services) every other day 
until the size of the calculated sample was achieved. á e 
sample size was calculated for an alpha error of 5% and 
the sample calculation of the first sampling was based on the 
lower number of errors per 1,000 items prescribed (3.2 er-
rors) identified in literature14. For the second sampling, the 
prevalence of errors (number of errors per 1,000 items pre-
scribed) identified in the first sampling (292.5 errors) was 
used as a reference for the sample calculation.
á e study followed these steps: design and validation 
of the data collection form; team training; first sampling, 
coding, quality control; entries into the data base; tabu-
lation and analysis; intervention, second sampling, cod-
ing; quality control; entries into the data base; tabulation, 
analysis and data comparison. á e intervention measures 
were implemented over 4 years (administrative managing) 
and designed on a base of error types identified in the first 
sampling, namely: 1) Introduction of the daily presence of 
a medical preceptor into each hospital clinic instructing 
residents and medical students about the prescription elab-
oration. 2) Elaboration of a manual of good prescription 
practices containing tips on how to avoid prescription er-
rors (delivered yearly to prescriptors)12. 3) Training about 
the rational use of drugs (based on the WHO method11 
and the elaborated manual12 with a semiannual periodic-
ity). 4) Availability of medical journals via web to the pre-
scriptors. 5) Clinical protocol elaboration. 6)  Resumption 
of medical-surgical sessions (monthly periodicity).
á e variables or variable groups studied were:
1. Readability: 
á e prescription was considered unreadable when at 
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least two investigators had found it difl cult to read what 
was written, resorting to the prescriptor for clarification.
2. Compliance with legal procedures15-18:
a) Patient’s name: the completeness (no abbreviations 
or omissions), the readability and the patient’s correct 
identification.
b) Prescription date and prescriptor signature: for 
both, presence and readability were evaluated.
c) Practice number: presence and readability were 
evaluated, being considered present when handwritten or 
imprinted.
d) Type of designation used for the drug: whether the 
prescribed drug was evaluated by using the commercial 
generic name or the chemical formula.
3. Compliance with institutional procedures:
a) Number of the patient’s record, bed and admission 
unit: the presence, readability and accuracy were evaluated.
b) Abbreviation use: an error was considered when the 
abbreviations were used for the drug name, the patient’s 
name, U and IU (for units and international units, respec-
tively) and when they could be confused with zero19,20.
4. Prescription error analysis:
a) Error existence: Each prescription contains one or 
more drug items and can contain one or more errors. Pre-
scription errors were defined as drug prescriptions involv-
ing wrong patient, drug, dose, frequency, administration 
route and/or pharmaceutical formulation, inappropriate 
indication, double or redundant therapeutics, document-
ed allergy to prescribed drugs, contraindicated therapy 
and absence of critical information (age, weight, serum 
creatinine, diagnosis, etc.) required for the drug dispensa-
tion and administration21. fl ey still include inappropriate 
treatment combination13 and inadequate duration of treat-
ment. Prescription drug manufacturer information (pack-
age leaflets), information available from Micromedex21 
and tertiary source22.
b) Clinically significant errors (CSE): they were identi-
fied and quantified according to Meyer23, that is, the CSE 
would be that occurred as a result from a prescription de-
cision or the elaboration process of the written prescrip-
tion in an unintentional way, generating or contributing 
to a significantly reduced probability of a timely and effec-
tive therapy or increasing the damage risk compared with 
the current practice standards24,25. fl ey were also used to 
identify the CSE existence, prescription drug manufac-
turer information (package inserts), information available 
from Micromedex21 and tertiary source22. fl e patients’ 
records were consulted to identify clinical conditions that 
could influence analyses such as weight, body area, results 
of laboratory tests, related symptoms (constipation, nau-
sea, vomiting), allergy record, disease history, habits (il-
legal drug use, alcoholism)26. 
c) fl e CSE types in prescriptions were classified by 
Dean27 as decision or writing errors. Decision errors were 
associated with the prescriptor’s understanding level 
about the patient’s clinical picture and the choice of the 
therapy drug. Writing errors are essential information 
communication failures associated with the prescription 
elaboration process (e.g.: prescribing a drug, but omit-
ting the administration route when it can be adminis-
tered by more than one route; prescription going to the 
wrong patient; prescribing the wrong drug).
d) Error severity: fl e CSE were subdivided into ac-
tual (detected afler their occurrence) and potential (pre-
scription mistakes which are detected and completely 
corrected before the drug administration). fl e severity 
was thus classified as follows: 1) For actual errors, the 
medication error categorization index is based on the 
National Coordinating Council for Medication Error Re-
porting and Prevention - B: an error occurred, but the 
patient was not reached; C: an error occurred, the patient 
was reached, but no damage was caused; D: an error oc-
curred, the patient was reached, monitoring to confirm 
no patient’s damage was caused was required and/or an 
intervention to prevent damage was required; E: an error 
occurred and it may have contributed to or resulted in 
transient damage for the patient, requiring an interven-
tion; F: an error occurred and may have contributed to 
or resulted in transient damage to the patient, causing a 
hospitalization extension28 was used. 2) For potential er-
rors, the adapted Lesar20 scale was used, identifying them 
as: AA:  potentially lethal; AB:  potentially serious and 
AC:  potentially significant (with a potential to produce 
an adverse effect).
fl e Lesar20 method adapted by Néri3 was used to de-
termine the prevalence of clinically significant errors 
(CSE) in prescriptions. fl e prescription process safety 
rate (PPSR) was calculated through the following formula: 
PPSR = 100% – rate of prescription CSE. fl e study obser-
vation units are related to individuals (patients) and drugs.
At the quality control stage, the CSE identified were 
evaluated independently by an intensivist and a pharma-
cist who is a Ph.D. in pharmacology for analysis consen-
sus. In the case of a disagreement, a specialist physician 
was consulted.
Values were expressed as mean and standard devia-
tion (X ± MSD) and processed by Epi Info. For proportion 
analysis, the z test was used to compare the prescrition CSE 
prevalence rate values and PPSR. For proportion analy-
sis in 2 x 2 tables, non-parametrical tests were used (X2, 
Fisher-Freeman-Halton). fl e statistical significance level 
considered was p < 0.05.
fl e study was approved by the Ethics Committee 
(protocols 193/02 and 356/05) according to the Resolu-
tion 196 of the National Health Council and the inves-
tigator was ethically obliged to intervene when an error 
was identified, either by preventing the error to reach the 
patient or by interrupting its course.
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RESULTS
 e number of collected prescriptions was 474 (3,460 
prescribed drugs) over the period of June 1 to 30, 2003 
(first sampling) and 140 prescriptions (1,030 prescribed 
drugs) in May 7 to 13, 2007 (second sampling).  e mean 
number of items per prescription was 10.77 ± 6.20 (first 
sampling) and 10.50 ± 5.69 (second sampling) (p = 0.645). 
In turn, the mean number of drugs per prescription was 
7.30 ± 4.70 and 7.36 ± 4.63 (p = 0.897), respectively, for the 
first and the second samplings.
Table 1 shows the occurrence of errors in complying 
with legal and institutional procedures. Incomplete and 
unreadable names [2003 (n = 168), 2007 (n = 38); p = 0.06] 
and prescriptor’s signature present but unreadable [2003 
(n = 464), 2007 (n = 120); p = 0.0001] were observed.
Abbreviation use was observed in about 98% of 
drugs prescribed in both periods (2003, n = 3,046; 2007, 
n  =  1,017). In 2003, abbreviations were more frequent 
for administration route (n = 2,980), dosing (n = 2,279), 
pharmaceutical formula (n  =  1,783) and drug name 
(n = 297). In 2007, they were more frequently used in dos-
ing (n = 634), administration route (n = 265), drug name 
(n = 80) and pharmaceutical formula (n = 10).  e abbre-
viation “U” use for unit was observed in both periods.
Generic denomination was used in 66.01% (n = 2284) 
of prescribed drugs in 2003 and in 69.61% (n  =  717) in 
the year of 2007 (p = 0.034). Commercial denomination 
was adopted, in 2003, in 30.75% (n  =  1064) drugs pre-
scribed and, in 2007, for 28.30% (n = 291) (p = 0.135).  e 
chemical formula was used in 3.24% (n  =  114) of drugs 
prescribed in 2003 and 2.14% (n = 22) in 2007 (p = 0.086).
Allergy information was absent in prescriptions col-
lected and the mention to the patient’s questioning about 
allergies was not found in 40.5% (n  =  192) and 53.57% 
(n = 75) of medical records in 2003 and 2007, respectively 
(p = 0.008). Information on weight was absent in 71.94% 
(2003; n  =  341) and 75.71% (2007; n  =  106) of medical 
records (p = 0.436).
Analyzed item (na; nb) Prescriptions 2003 Prescriptions 2007 X2 p
f % f %
Patient’s complete and readable name?  
(474; 140)
No 168 35.44 38 27.14
3.34 0.06cYes 306 64.56 102 72.86
Correct patient? 
(474; 140)
No 2 0.42 1 0.71
– 0.541
Yes 472 99.58 139 99.29
Is the medical record number readable?  
(474; 140)
No 58 12.24 9 6.43
374 0.05c
Yes 416 87.76 131 93.57
Is the medical record correct? 
(416; 131)
No 24 5.77 4 3.05
1.51 0.219c
Yes 392 94.23 127 96.95
Is the prescription date present and readable? 
(474; 140)
No 17 3.59 2 1.43
1.68 0.16c
Yes 457 96.41 138 98.57
Is the practice number imprinted or readable? 
(474; 140)
No 16 3.38 8 5.71
1.58 0.209c
Yes 458 96.62 132 94.29
The bed number is readable? 
(474; 140)
No 0 0.00 1 0.71
– 2.28d
Yes 474 100.00 139 99.29
Is the bed correct? 
(474; 139)
No 3 0.63 0 0.00
– 0.999d
Yes 471 99.37 139 100.00
Is the admission unit readable? 
(474; 140)
No 23 4.85 3 2.14
1.96 0.162c
Yes 451 95.15 137 97.86
Is the admission unit correct? 
(451; 137)
No 14 3.10 0 0.00
4.36 0.036c
Yes 437 96.90 137 100.00
Is the prescriptor’s signature present* and 
readable? (474; 140)
No 464 97.89 120 85.71
34.47 0.0001c
Yes 10 2.11 20 14.29
*The prescriptor’s signature was present in 100% of the prescriptions analyzed. na, number of prescriptions analyzed in 2003 for the item at 
issue. nb, number of prescriptions analyzed in 2007 for the item at issue. c Chi-Square Test. d Fisher-Freeman-Halton test; f, frequency.
Table 1 – Prescription distribution according to whether there are legal and institutional components or not in a university 
hospital in Northeastern Brazil in the years of 2003 and 2007
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 e readability analysis of drugs prescribed revealed, 
in 2003, 99.54% of them (n = 3,444) were readable and, 
in 2007, 92.72% (n = 955) (p = 0.001). Omission of one 
or more items of information relevant for the dispensa-
tion safety and the prescribed drug administration was 
found, being identified that, in 2003, 75.35% of drugs 
(n = 2,607) had omission of relevant information, where-
as this percentage was 79.22% (n = 816) (p = 0.012) in 
2007.  e omitted information was: infusion rate [2003 
(78.22%, n = 2,706); 2007 (74.44%, n = 753)]; concentra-
tion [2003 (54.02%, n = 1869); 2007 (52.77%, n = 534) 
and pharmaceutical formula [2003 (53.12%, n = 1,838); 
2007 (55.15%, n = 558)].
At the first sampling (2003), 8,271 prescription er-
rors were identified in 474 prescriptions containing 
3,460 drugs prescribed and, out of these errors, 12.24% 
(n = 1012) were CSE, with this number ranging from 1 
to 10 CSE/prescription (mean  =  2.60 ± 0.10). In 2007, 
all prescriptions had errors (n = 140), adding up to 2,608 
errors for 1,030 drugs prescribed, from which 9.55% 
(n = 249) were CSE, ranging from 1 to 9 CSE/prescrip-
tion (mean = 2.50 ± 1.80). By adding the two-period er-
rors and dividing by the total prescriptions collected, a 
mean of 2 CSE/prescription was obtained, with 75.34% 
(n = 950) of errors concentrated in the writing process. 
 e drugs most frequently involved in CSE, in both sam-
plings, were dipyrone [2003 (11.74%); 2007 (10.03%)], 
regular insulin [2003 (7.28%); 2007 (8.70%)] and digoxin 
[2003 (3.53%); 2007 (10.03%)].
 e CSE were categorized into writing and decision 
errors.  e error percentage occurred in the writing pro-
cess was, in 2003, 75.39% (n = 763) and, in 2007, 75.10% 
(n = 187) (p = 0.987) (Table 2).
As for errors in the decision process, in 2003, the 
occurrence of 249 CSE (24.6%) and, in 2007, 24.90% 
(n = 62) (p = 0.961) was observed.  e types of decision 
errors and their frequencies are shown in Table 2.
In 2003, 98.4% (n = 112) of CSE were potential errors 
and, in 2007, 100% (n = 249). As for severity, CSE were 
distributed as shown in Table 3.
When prescription CSE prevalence rates were calcu-
lated, in 2003, 29.25% and, in 2007, 24.20% were iden-
tified (z = 2.99; p = 0.003), creating a prescription pro-
cess safety rate, in 2003, of 70.75% and, in 2007, 75.80% 
(z = 3.30; p = 0.0001).
DISCUSSION
á e results achieved bear out findings in Brazilian and 
international studies6,8,19,29-32 and showed prescription er-
rors are common and should be faced by practitioners 
involved in health care, mainly in teaching hospitals, in 
which the safety culture, if incorporated over the practi-
tioners’ graduation, can result in health system changes.
á e prescriptions analyzed in both phases had a mean 
number of items and drugs statistically similar, indicat-
ing the reproducibility of the method used, as well as the 
fact that patients are given a polypharmacy, favoring er-
ror occurrence3,30. á e mean number of drugs per pre-
scription was similar to that found by Cruciol-Souza33 
in a teaching hospital in Paraná, stressing the need of a 
higher level of attention to prescriptions in this specific 
hospital group because of the confluence of factors asso-
ciated with the higher error tendency3.
á e prescriptor’s name, his/her signature and prac-
tice number in the Council, when associated, give the 
prescription legal validity and, when this information 
is unreadable or missing, prescriptions should not be 
dispensed or fulfilled. á is legal optics further contains 
discussions that are of technical and practical in nature, 
making the hospital routine more diá cult. á e results 
obtained in 2003 and 2007 regarding the prescriptor’s 
identification, were better than Sebastião’s34, who iden-
tified the practice number was missing in 83% of pre-
scriptions, the prescriptor’s signature in 19.2% and the 
Type
2003 2007
f % f % Z p
Error in the writing process (n=763)a (n=187)a
One or more items of the patient’s 
identification are missing
210 27.5 43 23.0 1.16 0.248
Ambiguous/confused prescription 210 27.5 33 17.6 2.69 0.007
Infusion rate missing* 111 14.5 27 14.4 0.08 0.935
Error in the decision process (n=249)b (n=62)b
Potentially significant drug interaction 150 60.2 29 46.8 1.77 0.077
Prescription of a drug not indicated for the 
patient
21 8.4 8 12.9 0.85 0.397
*Drugs requiring the information to assure the dispensation and administration safety. a The number between brackets represents the total 
errors in the writing process; b The number between brackets represents the total errors in the decision process; f, frequency.
Table 2 – Prevalence of main types of clinically significant errors in writing and decision processes identified in the years of 
2003 and 2007 in a university hospital in Northeastern Brazil
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practitioner’s name in 45.2%.  e prescriptor’s signature 
readability had a statistically significant improvement be-
tween 2003 and 2007.
In addition to the items aforementioned, the date pro-
vides the prescription with validity which, in a hospital 
setting, usually lasts 24 hours. When the date is consid-
ered, the results achieved in the samplings are similar to 
Sebastião’s33 (97.2%) and Miasso’s29 (96%), but higher than 
Rosa’s19 (90.6%).
 e use of abbreviations and symbols in prescriptions 
is pointed as an error-related factor18,19, and at times these 
errors are fatal35. Several prescriptors see abbreviation use 
as a way of saving time, however they have no thoughts of 
the time spent by the other practitioners in clarifying the 
doubts35 and of the risks resulting from mistaken interpre-
tations. Moreover, the abbreviation use is contrary to the 
Decree no. 20.931/3214, which determines the prescription 
must be made in full and must not be made in a secret 
mode.  e practice of abbreviations was widely identified 
in both samplings, being similar to Miasso’s29 results, with 
the drug name abbreviation and use of “U” for “unit” being 
highlighted, both facts described by Cohen36 as significant 
safety issues.  e use of “U” is included in the abbreviation 
list prohibited by the Joint Commission on the Accredita-
tion of Health Care Organizations35. In Brazil, in 2007, the 
National Health Surveillance Agency (Anvisa) discussed 
the standardization of names, concepts and abbreviations 
in pharmaceutical forms of drugs to assure a common un-
derstanding37.
 e use of the generic denomination in prescription 
in both study years was twice the value found by Sebastião 
(30.2%)34. By comparing the years of 2003 and 2007, a sig-
nificant increase in generic denomination adoption was 
shown, but the legal provision regulating the issue has not 
been wholly fulfilled17.
Information such as weight and allergy report is a basic 
tool for the safety of drug dispensation and administration3; 
however, this data is oen missing in the medical record 
and in a similar level in both periods, in agreement with 
Devine’s38 data. Concerning allergy, there was a significant 
increase in the percentage of medical records missing an 
answer the patient should have given to the question asked 
about it, which is worrisome, since the non-documentation 
exposes health care users to an unnecessary and prevent-
able damage risk. According to Runciman39, over 75% of 
prior drug allergic reactions are not found in the medical 
record.  is data stresses the need of further emphasis on 
good documentation practice adoption during the prescrip-
tor’s training3.
 e low readability of prescriptions, mainly those 
handwritten19,29, has been indicated as a major cause for 
communication failure among practitioners involved in 
hospital care and a factor contributing to medication er-
rors19,29,30,32,40,41. Despite showing a readability result over 
90%, a significant reduction in prescription readability was 
found between 2003 and 2007, indicating a higher prob-
ability of patient damage.  ese findings can be minimized 
from the adoption of the electronic prescription42 and stress 
the need of a review in the prescriptor’s training43.
Type 2003 2007
Z p
f % f %
AA – Potential error: Potentially fatal 79 7.8 16 6.4 0.62 0.538
AB – Potential error: Potentially serious 200 20 48 19 0.09 0.929
AC – Potential error: Potentially significant (with potential 
to produce an adverse effect)
717 71 185 74 1.02 0.309
B – Actual error: an error occurred, but it did not reach 
the patient
1 0.1 – – 0.75 0.453
C – Actual error: an error occurred, reached the patient, 
but it caused no damage
2 0.2 – – 0.18 0.859
D – Actual error: an error occurred, reached the patient, 
monitoring to confirm it had not resulted in damage to the 
patient was required and/or an intervention to prevent the 
damage was required
6 0.6 – – 0.71 0.475
E – Actual error: an error occurred and it may have 
contributed to or resulted in transient damage to the 
patient, requiring an intervention
6 0.6 – – 0.71 0.475
F – Actual error: an error occurred may have contributed 
to or resulted in transient damage to the patient, causing a 
hospitalization extension
1 0.1 – – 0.75 0.453
Total 1,012 100 249 100 – –
f,  frequency.
Table 3 – Distribution of clinically significant prescription errors according to severity identified in the years of 2003 and 
2007 in a university hospital in Northeastern Brazil
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Similarly, information missing is considered a major 
fault in the prescription process, negatively influencing 
the communication quality29,33. When this indicator was 
evaluated, a significant increase in the percentage of miss-
ing information relevant to the safety of drug dispensation 
and administration was observed.  e concentration and 
pharmaceutical formulation figure among the informa-
tion most frequently missing in both samplings, an issue 
also reported by Rosa19, Miasso29 and Sebastião34 in other 
Brazilian hospitals.  e infusion rate missing also identi-
fied can lead to an Adverse Drug Reaction infusion rate-
dependent, as in the case of the red man syndrome related 
to the quick vancomycin infusion3.
 e analysis by segment revealed writing errors had a 
similar behavior and represented more than three quarts 
of the total in both periods. In this setting, the results were 
similar to Rosa’s19, Devine’s38 and Dean’s44.  e writing er-
rors also had a similar behavior between 2003 and 2007. 
Decision errors are considered more complex to be pre-
vented than the writing errors3.
Among the writing CSE, missing patient identification 
items (name, medical record number, bed, clinic or ser-
vice where he/she was admitted) were predominant, mak-
ing higher the chance of a patient receive drugs that were 
not prescribed for him(her) and suffer damage resulting 
from this exchange7. In this study, the patient’s name on 
the prescription had a high inadequacy (incomplete, with 
an abbreviation, and unreadable) percentage, contributing 
to a prescription exchange between namesakes, a possibil-
ity already described in literature44 which can be prevented 
through the patient’s appropriate identification.
 e ambiguous/confused prescription had its per-
centage significantly reduced, comparing 2003 with 
2007, but this result still represents twice the frequency 
identified by Ridley32 in a prescription study in an inten-
sive care unit (ICU).
Regarding CSE in the decision process, the prevalence 
was observed as similar in both periods, but they had a 
lower frequency than writing errors, with a significantly 
reduced tendency for drug interaction being observed. 
 e severity of the decision errors, according to Dean44, 
is greater than that with writing errors.  e lack of knowl-
edge and information about the patient was pointed by 
Louro30 as a factor related to prescription errors.
Drug interaction and drug prescription with no indi-
cation for the patient were predominant decision errors in 
the samplings, and occurrence percentage of the interac-
tion, in relation to the total CSE identified, was about three 
to five times as high as those identified by Devine38 (2.8%) 
and Louro30 (3.4%), respectively.  e percentage of clini-
cally significant drug interactions identified in this study 
was similar to that obtained by Hammes45 in an ICU in 
Santa Catarina, Brazil. When the prescription of a con-
traindicated drug for the patient according to preexisting 
conditions reported in the medical record was analyzed, 
a significantly increased occurrence was found. Both er-
rors are relevant and deserve to be considered in the re-
flection process aiming at the prescriptors’ teaching im-
provement46.
 e analysis of three drugs more frequently involved 
in CSE revealed that two of them are classified as poten-
tially dangerous drugs associated with more serious er-
rors19. In this study and in Devine’s38 study, most errors 
were potential, with the minority of them being classified 
as potentially fatal. Regarding the actual errors, some of 
them reached the patient, resulting in a transient damage, 
with a prevalence 3.4 times as higher as that identified by 
Devine38 (0.2%).
 e prescription CSE prevalence rate suffered a sig-
nificant reduction between the periods and had a mean 
percentage similar to Devine’s (27.4%)38.  e reduced 
CSE prevalence rate, resulting from the quantitative re-
duction of clinically significant errors, provided a sig-
nificant increase in this process safety rate; however, a 
reduced severity in the errors identified between the pe-
riods was not found.
Factors contributing mostly to elevate the PPSR were 
the increased percentage of a correct recording of the pa-
tient’s hospitalization unit, signature readability on the pre-
scription, increased generic denomination use and reduc-
tion of drugs prescribed in an ambiguous/confused way.
 e findings suggest an improvement of the prescrip-
tion process quality between the study periods, but there 
was no influence on the error severity. Ross46 reports there 
is little evidence in the present literature instructing medi-
cal schools on how to prepare students to prescribe and 
that the use of the WHO Guide for a Good Medical Pre-
scription11 is the only model with evidence of prescrip-
tion improvement.  e WHO method was adopted in 
this study and may have contributed to reduced ECS.  e 
reduced occurrence of errors following the education pro-
gram adoption focused on prescriptors was also shown by 
other authors4,18,24.
CONCLUSION
 e prescription process is complex and permeated by 
errors. Prescription errors are usually multifactorial and 
arise from active faults or conditions error-inducing, usu-
ally acting together to cause them. Face of this complexity, 
solutions involving only one cause, such as lack of knowl-
edge, seem to have limited benefits.
 e confrontation of the prescription error issue is a 
world challenge and must be an institutional goal. In this 
study, the statistical increase in the prescription process 
safety rate was identified, influenced by the quantitative 
reduction in clinically significant errors between 2003 and 
2007, but the error severity was not changed, indicating 
the steps taken were ineffective in reducing the severity.
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